Arvinas Grants Stock Options to New Hire Outside Incentive Plan
Arvinas issued an inducement equity award to one new employee, including options on 64,766 shares and 42,388 restricted stock units.
Arvinas, Inc. (Nasdaq: ARVN), a New Haven, Connecticut-based clinical-stage biotechnology company focused on targeted protein degradation therapies, disclosed Tuesday that it granted an equity inducement award to a newly hired employee effective September 28, 2026.
The package consists of an option to purchase 64,766 shares of common stock alongside 42,388 restricted stock units. Both components were granted under Nasdaq Listing Rule 5635(c)(4), a provision that allows companies to issue equity as an employment inducement outside of a formal stockholder-approved incentive plan.
Read more MSIG USA Names Oscar Aguilar to Lead E&S Property Unit →
The use of Rule 5635(c)(4) is a standard mechanism biotechnology and other Nasdaq-listed firms employ to attract senior or specialized talent without tapping the share reserve of their existing equity compensation plans. Arvinas did not identify the new employee or their role in the announcement.
Arvinas develops a novel class of therapeutics designed to harness the body's natural protein disposal system, known as PROTAC technology, to selectively eliminate disease-causing proteins. The company's pipeline targets oncology and other serious diseases.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
